HERON THERAPEUTICS, INC. /DE/ 8K

Heron Therapeutics reported Q2 2026 results, amended its Hercules Capital credit facility to reset covenants and reduce principal, withdrew full-year 2026 financial guidance due to patent uncertainty and operating changes, and disclosed it is considering strategic alternatives.

On August 10, 2026, Heron Therapeutics, Inc. reported its second quarter 2026 financial results, disclosing total net revenue of $37.7 million (up 9% sequentially but essentially flat year-over-year), highlighted strong growth in its Acute Care franchise (including ZYNRELEF and APONVIE) offset by declines in Oncology Supportive Care revenues, and noted a net loss of $5.5 million for the quarter. The company amended its credit facility with Hercules Capital, resetting financial covenants through 2027 and securing an aggregate potential $17.5 million reduction of outstanding principal ($13.5 million at execution and an additional $4 million scheduled on or before September 15, 2026). Citing uncertainty following a June 2026 U.S. District Court decision affecting patents covering its key product CINVANTI, associated difficulty forecasting potential generic entry, and changes to its operating plan including pausing a planned sales force expansion and tightening spending, Heron withdrew its previously issued full-year 2026 guidance for net product sales and Adjusted EBITDA and stated that investors should no longer rely on that guidance, while also indicating that it is evaluating strategic alternatives without a defined timetable.

Filing Facts

CIK

818033

Ticker

-

Form

8K

Source Type

sec

Accession

0001193125-26-341300

Alert Tier

7